Table 2.
Antimicrobial activity of JNJ-Q2 and comparator antimicrobials against 511 S. aureus isolates by fluoroquinolone and methicillin resistance status
| Organism (no. of isolates tested) and antimicrobial agenta | MIC (μg/ml) |
%S/%Rb |
|||
|---|---|---|---|---|---|
| MIC50 | MIC90 | Range | CLSI | EUCAST | |
| All isolates (511) | |||||
| JNJ-Q2 | 0.12 | 0.5 | ≤0.008–4 | —/— | —/— |
| Moxifloxacin | 2 | >16 | 0.03–>16 | 20.0/78.1 | 20.0/78.1 |
| Levofloxacin | 8 | >16 | 0.12–>16 | 20.0/80.0 | 20.0/80.0 |
| Ciprofloxacin | 16 | >16 | 0.12–>16 | 20.0/80.0 | 20.0/80.0 |
| Oxacillin | >2 | >2 | ≤0.25–>2 | 29.9/70.1 | 29.9/70.1 |
| Penicillin | 32 | >32 | ≤0.015–>32 | 10.0/90.0 | 10.0/90.0 |
| Erythromycin | >2 | >2 | ≤0.25–>2 | 16.0/83.8 | 16.0/83.8 |
| Clindamycin | ≤0.25 | >2 | ≤0.25–>2 | 70.8/28.8 | 70.6/29.2 |
| Linezolid | 2 | 2 | 0.5–4 | 100.0/0.0 | 100.0/0.0 |
| Tetracycline | ≤2 | ≤2 | ≤2–>8 | 94.9/4.5 | 93.5/6.5 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>2 | 98.2/1.8 | 98.2/1.8 |
| Daptomycin | 0.5 | 0.5 | 0.12–1 | 100.0/— | 100.0/0.0 |
| Vancomycin | 1 | 1 | 0.5–2 | 100.0/0.0 | 100.0/0.0 |
| FQR MRSA (308) | |||||
| JNJ-Q2 | 0.25 | 1 | 0.12–4 | —/— | —/— |
| Moxifloxacin | 4 | >16 | 1–>16 | 0.0/97.7 | 0.0/97.7 |
| Levofloxacin | 16 | >16 | 4–>16 | 0.0/100.0 | 0.0/100.0 |
| Ciprofloxacin | >16 | >16 | 8–>16 | 0.0/100.0 | 0.0/100.0 |
| Erythromycin | >2 | >2 | ≤0.25–>2 | 6.5/93.5 | 6.5/93.5 |
| Clindamycin | ≤0.25 | >2 | ≤0.25–>2 | 61.7/38.0 | 61.4/38.3 |
| Linezolid | 2 | 2 | 0.5–4 | 100.0/0.0 | 100.0/0.0 |
| Tetracycline | ≤2 | ≤2 | ≤2–>8 | 95.8/3.6 | 93.5/6.5 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>2 | 98.1/1.9 | 98.1/1.9 |
| Daptomycin | 0.5 | 0.5 | 0.12–1 | 100.0/— | 100.0/0.0 |
| Vancomycin | 1 | 1 | 0.5–2 | 100.0/0.0 | 100.0/0.0 |
| FQR MSSA (101) | |||||
| JNJ-Q2 | 0.25 | 0.5 | 0.12–2 | —/— | —/— |
| Moxifloxacin | 2 | 8 | 1–>16 | 0.0/97.0 | 0.0/97.0 |
| Levofloxacin | 8 | >16 | 4–>16 | 0.0/100.0 | 0.0/100.0 |
| Ciprofloxacin | >16 | >16 | 8–>16 | 0.0/100.0 | 0.0/100.0 |
| Erythromycin | >2 | >2 | ≤0.25–>2 | 15.8/84.2 | 15.8/84.2 |
| Clindamycin | ≤0.25 | >2 | ≤0.25–>2 | 71.3/28.7 | 71.3/28.7 |
| Linezolid | 2 | 2 | 1–2 | 100.0/0.0 | 100.0/0.0 |
| Tetracycline | ≤2 | ≤2 | ≤2–>8 | 96.0/4.0 | 96.0/4.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–>2 | 97.0/3.0 | 97.0/3.0 |
| Daptomycin | 0.25 | 0.5 | 0.12–1 | 100.0/— | 100.0/0.0 |
| Vancomycin | 1 | 1 | 0.5–2 | 100.0/0.0 | 100.0/0.0 |
| FQS MRSA (50) | |||||
| JNJ-Q2 | ≤0.008 | ≤0.008 | ≤0.008–0.015 | —/— | —/— |
| Moxifloxacin | 0.06 | 0.06 | 0.03–0.12 | 100.0/0.0 | 100.0/0.0 |
| Levofloxacin | 0.25 | 0.25 | 0.12–0.5 | 100.0/0.0 | 100.0/0.0 |
| Ciprofloxacin | 0.5 | 0.5 | 0.25–1 | 100.0/0.0 | 100.0/0.0 |
| Erythromycin | >2 | >2 | ≤0.25–>2 | 6.0/92.0 | 6.0/92.0 |
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25–>2 | 98.0/2.0 | 98.0/2.0 |
| Linezolid | 2 | 2 | 1–2 | 100.0/0.0 | 100.0/0.0 |
| Tetracycline | ≤2 | ≤2 | ≤2–>8 | 92.0/6.0 | 92.0/8.0 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5 | 100.0/0.0 | 100.0/0.0 |
| Daptomycin | 0.5 | 0.5 | 0.25–0.5 | 100.0/— | 100.0/0.0 |
| Vancomycin | 1 | 1 | 0.5–1 | 100.0/0.0 | 100.0/0.0 |
| FQS MSSA (52) | |||||
| JNJ-Q2 | ≤0.008 | 0.015 | ≤0.008–0.015 | —/— | —/— |
| Moxifloxacin | 0.06 | 0.06 | 0.03–0.12 | 100.0/0.0 | 100.0/0.0 |
| Levofloxacin | 0.25 | 0.25 | 0.12–0.5 | 100.0/0.0 | 100.0/0.0 |
| Ciprofloxacin | 0.5 | 0.5 | 0.12–1 | 100.0/0.0 | 100.0/0.0 |
| Erythromycin | ≤0.25 | >2 | ≤0.25–>2 | 82.7/17.3 | 82.7/17.3 |
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25–1 | 98.1/0.0 | 98.1/1.9 |
| Linezolid | 2 | 2 | 1–2 | 100.0/0.0 | 100.0/0.0 |
| Tetracycline | ≤2 | ≤2 | ≤2–>8 | 90.4/9.6 | 90.4/9.6 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | ≤0.5–2 | 100.0/0.0 | 100.0/0.0 |
| Daptomycin | 0.5 | 0.5 | 0.12–1 | 100.0/— | 100.0/0.0 |
| Vancomycin | 1 | 1 | 0.5–2 | 100.0/0.0 | 100.0/0.0 |